SLNO vs. BLCO, INSP, NARI, PRCT, NVST, IRTC, NVCR, LIVN, ENOV, and WRBY
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.
Soleno Therapeutics vs.
Bausch + Lomb (NYSE:BLCO) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Soleno Therapeutics has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics received 275 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 72.09% of users gave Soleno Therapeutics an outperform vote while only 41.67% of users gave Bausch + Lomb an outperform vote.
Bausch + Lomb has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.47, suggesting that its share price is 247% less volatile than the S&P 500.
In the previous week, Bausch + Lomb had 5 more articles in the media than Soleno Therapeutics. MarketBeat recorded 7 mentions for Bausch + Lomb and 2 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.83 beat Bausch + Lomb's score of 0.42 indicating that Soleno Therapeutics is being referred to more favorably in the news media.
Bausch + Lomb currently has a consensus target price of $20.42, indicating a potential upside of 20.01%. Soleno Therapeutics has a consensus target price of $74.83, indicating a potential upside of 54.52%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Bausch + Lomb.
Soleno Therapeutics has a net margin of 0.00% compared to Bausch + Lomb's net margin of -7.86%. Bausch + Lomb's return on equity of 3.17% beat Soleno Therapeutics' return on equity.
11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 0.2% of Bausch + Lomb shares are held by company insiders. Comparatively, 12.3% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Soleno Therapeutics beats Bausch + Lomb on 12 of the 18 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLNO) was last updated on 1/22/2025 by MarketBeat.com Staff
Free SLNO Stock Alerts